Valuation: Mangalam Drugs & Organics Limited

Market Cap 439M 4.6M 4M 3.72M 3.42M 6.45M 6.55M 43.87M 17.22M 219M 17.27M 16.89M 733M P/E 2024
-16.2x
P/E 2025 17.5x
Enterprise Value 1.38B 14.41M 12.53M 11.66M 10.7M 20.21M 20.53M 137M 53.94M 685M 54.11M 52.93M 2.3B EV / Sales 2024
0.69x
EV / Sales 2025 0.66x
Free-Float
62.31%
Yield 2024 *
-
Yield 2025 -
18/06 Mangalam Drugs and Organics Ltd. Defaults on Loan Obligations to Bank of Baroda and Bank of Maharashtra CI
14/05 Mangalam Drugs & Organics Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
17/04 Mangalam Drugs & Organics Limited Announces Resignation of Anuradha Pandey as Company Secretary & Compliance Officer, Effective March 29, 2026 CI
16/04 Mangalam Drugs and Organics Limited Defaults on Loan Obligations Exceeding 30 Days with INR 95.197 Million to Bank of Maharashtra and INR 60.608 Million to Bank of Baroda CI
26/03 Mangalam Drugs and Organics Limited Appoints Shweta Patel as Company Secretary & Compliance Officer, Effective April 1, 2026 CI
17/03 Mangalam Drugs and Organics Limited Reports Loan Defaults Exceeding 30 Days on Bank Borrowings CI
17/03 Mangalam Drugs and Organics Limited Defaults on Loan Obligations to Bank of Maharashtra and Bank of Baroda CI
17/03 Mangalam Drugs and Organics Limited Defaults on Bank Loan Obligations Exceeding 30 Days with INR 70.705 Million to Bank of Maharashtra and INR 44.677 Million to Bank of Baroda CI
17/03 Mangalam Drugs and Organics defaults on loan obligations to Bank of Baroda, Bank of Maharashtra RE
06/02 Mangalam Drugs and Organics names Jeevan M. Dalvi as CFO RE
06/02 Mangalam Drugs and Organics Limited Approves the Appointment of Jeevan Mukund Dalvi as Chief Financial Officer, Effective February 6, 2026 CI
17/01 Mangalam Drugs and Organics Limited Announces Resignation of Rukmesh P. Dhandhania as Independent Director and Member of Audit and Nomination and Remuneration Committees, Effective January 16, 2026 CI
16/01 Mangalam Drugs & Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
1 day+0.15%
1 week-0.40%
1 month-3.66%
3 months-8.04%
6 months-25.11%
Current year-1.45%
1 week 26.33
Extreme 26.33
27.8
1 month 26.33
Extreme 26.33
29.3
Current year 26.33
Extreme 26.33
54.4
1 year 22.8
Extreme 22.8
90.85
3 years 22.8
Extreme 22.8
144.99
5 years 22.8
Extreme 22.8
194.15
10 years 20.65
Extreme 20.65
225.7
Manager TitleAgeSince
Chief Executive Officer 72 30/09/2011
Director of Finance/CFO - 06/02/2026
Compliance Officer 27 01/04/2026
Director TitleAgeSince
Chairman 72 02/02/2010
Director/Board Member 71 21/03/2021
Director/Board Member 75 05/02/2015
Change 5-day change 1-year change 3-year change Capi.($)
+0.15%-0.40% - - 4.48M
-0.53%+2.54%+16.63%+74.09% 50.29B
-1.81%-0.49%+51.99%+112.44% 37.24B
+0.46%+4.44%-5.24%+25.38% 12.41B
+1.05%+1.63%+16.19%+78.22% 11.65B
+0.19%+0.38%+31.58%+134.38% 9.17B
-2.99%-2.09%+41.02%-8.36% 7.24B
+0.51%+1.46%+12.17%+32.88% 6.8B
-.--%+0.14% - - 6.79B
+1.99%+1.91%+4.68%+183.54% 6.47B
Average -0.10%+1.99%+21.13%+79.07% 16.45B
Weighted average by Cap. -0.54%+2.70%+25.45%+82.98%

Financials

2024 2025
Net sales 3.67B 38.48M 33.45M 31.14M 28.59M 53.99M 54.82M 367M 144M 1.83B 145M 141M 6.13B 3.18B 33.27M 28.92M 26.92M 24.71M 46.67M 47.39M 317M 125M 1.58B 125M 122M 5.3B
Net income -90.72M -950K -826K -769K -706K -1.33M -1.35M -9.06M -3.56M -45.16M -3.57M -3.49M -151M 67.21M 704K 612K 570K 523K 988K 1M 6.71M 2.64M 33.46M 2.64M 2.59M 112M
Net Debt 1.06B 11.08M 9.63M 8.97M 8.23M 15.55M 15.79M 106M 41.49M 527M 41.63M 40.71M 1.77B 936M 9.81M 8.53M 7.94M 7.29M 13.76M 13.97M 93.56M 36.72M 466M 36.84M 36.03M 1.56B
Logo Mangalam Drugs & Organics Limited
Mangalam Drugs and Organics Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs) and intermediates. Under the Company's Fight Malaria Program, it supplies anti-malaria APIs worldwide. Its products include API, intermediates and specialty chemicals. Its API products include acyclovir, amodiaquine, artemether, artesunate, atazanavir sulfate, bisoprolol fumarate, chloroquine phosphate, furosemide and dolutegravir sodium. The Company's intermediates products include 4,6-Dichloro-5-Methoxy Pyrimidine; 4,7- dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base, and tenofovir disoproxil base. Its specialty chemical products include L (+)-menthol; 2,3-dihydrophthalazine-1,4-dione or phthalazine-1,4-dione, and 4-cynoethyl-2-methyl phenol. Its pipeline APIs (under development) include Ganaplacide (IH), Tafenoquine Succinate (IH) and Pretomanid (IH). Its pipeline APIs (developed for research and development) is Bictegravir Na (IH).
Employees
480
Date Price Change Volume
31/07/26 INR 27.11 +0.15% 8,754
30/07/26 INR 27.07 -0.26% 24,198
29/07/26 INR 27.14 -1.17% 25,640
28/07/26 INR 27.46 +0.15% 18,804
27/07/26 INR 27.42 +0.73% 8,630